ArticleCureus2026
Demographic Analysis of Patients With Ulcerative Colitis Undergoing Restorative Proctocolectomy With Ileal Pouch-Anal Anastomosis: A Single-Center Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUlcerative colitis (UC) is a chronic relapsing inflammatory bowel disease limited to the colonic mucosa, with rising incidence and prevalence in many regions of the world, including Latin America. A subset of patients requires colectomy for medically refractory disease, acute severe colitis, dysplasia, or malignancy, for whom restorative proctocolectomy with ileal pouch-anal anastomosis (RPC-IPAA) is the preferred restorative procedure. Pouch-related complications -- including pouchitis, chronic antibiotic-refractory pouchitis (CARP), pouch failure, and diagnostic reclassification to Crohn's disease -- represent major clinical challenges; however, published institutional data on RPC-IPAA outcomes from hospital centers in Mexico and Latin America remain exceptionally scarce. This descriptive single-center study aimed to describe the demographic profile, operative characteristics, and predefined pouch-related complications in patients with UC who underwent RPC-IPAA at a tertiary referral center in Mexico.
methodsA retrospective observational study was conducted at the Inflammatory Bowel Disease Clinic of the Coloproctology Service, Hospital General de México "Dr. Eduardo Liceaga," reviewing medical records of UC patients who underwent RPC-IPAA between 2010 and 2022. Demographic and clinical variables were analyzed using IBM SPSS Statistics, version 29 (IBM Corp., Armonk, NY). Quantitative variables were summarized as mean ± SD and categorical variables as frequencies and percentages. Pouchitis was diagnosed using the Pouchitis Disease Activity Index (PDAI ≥7). CARP was defined as active pouchitis (PDAI ≥7) persisting despite at least four consecutive weeks of antibiotic therapy and failure of at least two sequential antibiotic regimens. Postoperative follow-up was calculated from the date of pouch creation to the last clinical encounter.
resultsFourteen patients were included; 8 (57.1%) were women. Mean age was 34.86 ± 7.94 years. All patients had Montreal E3 pancolitis. The mean interval between UC diagnosis and pouch creation was 3.86 ± 1.81 years. The median postoperative follow-up was 6.2 years (IQR: 3.4-9.1 years; range: 0.5-12.0 years). J-pouch construction was performed in 13 (92.9%) patients and D-pouch in 1 (7.1%). One (7.1%) patient experienced pouch failure and underwent W-pouch reconstruction. One (7.1%) patient originally diagnosed with UC E3 was subsequently reclassified as Crohn's disease (Montreal A2L4B2) and is currently receiving anti-interleukin-12/23 therapy (ustekinumab). Pouchitis occurred in 4 (28.6%) patients; all developed CARP and are currently being treated with anti-integrin therapy (vedolizumab).
conclusionsIn this descriptive single-center study, RPC-IPAA was predominantly performed with J-pouch construction, achieving durable pouch preservation over a median follow-up of 6.2 years. Pouch-related complications -- including CARP, pouch failure, and diagnostic reclassification to Crohn's disease -- emerged as important sources of morbidity requiring escalation to advanced biologic therapy and, in selected cases, surgical reintervention. These findings underscore that successful pouch surgery depends on structured individualized surveillance, dedicated multidisciplinary care, and timely access to biologic therapies throughout the postoperative course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.